哌甲酯治疗注意缺陷多动障碍的研究进展

胡春水; 江文庆; 沈红艳; 杜亚松

doi:10.11852/zgetbjzz2018-26-10-16

PDF(503 KB)

中国儿童保健杂志 ›› 2018, Vol. 26 ›› Issue (10) : 1104-1106. DOI: 10.11852/zgetbjzz2018-26-10-16

综述与讲座

哌甲酯治疗注意缺陷多动障碍的研究进展

胡春水¹, 江文庆², 沈红艳¹, 杜亚松²

作者信息 +

Research progress on methylphenidate in the treatment of attention deficit hyperactivity disorder

HU Chun-shui¹, JIANG Wen-qing², SHEN Hong-yan¹, DU Ya-song²

Author information +

文章历史 +

摘要

哌甲酯是治疗注意缺陷多动障碍(ADHD)的一线药物,能够改善ADHD临床症状和社会功能。本应有更多的ADHD儿童从哌甲酯治疗中获益,但是由于对哌甲酯不良反应过度担心,患儿得不到合适的治疗,造成疾病负担加重。本文主要从哌甲酯治疗ADHD的疗效、不良反应、与托莫西汀的比较等几个方面,对哌甲酯治疗ADHD做一综述。

Abstract

Methylphenidate is a representative drug for attention deficit hyperactivity disorder (ADHD).It helps to control symptoms and to improve social function.More children with ADHD should have benefit from methylphenidate treatment.But patients can not get proper treatment because of their fear of side effects.This review will focus on the efficacy and side effect of methylphenidate,and make comparison between methylphenidate and atomoxetine.

导出引用

胡春水, 江文庆, 沈红艳, 杜亚松. 哌甲酯治疗注意缺陷多动障碍的研究进展[J]. 中国儿童保健杂志. 2018, 26(10): 1104-1106 https://doi.org/10.11852/zgetbjzz2018-26-10-16

HU Chun-shui, JIANG Wen-qing, SHEN Hong-yan, DU Ya-song. Research progress on methylphenidate in the treatment of attention deficit hyperactivity disorder[J]. Chinese Journal of Child Health Care. 2018, 26(10): 1104-1106 https://doi.org/10.11852/zgetbjzz2018-26-10-16

中图分类号： R179

参考文献

[1] American Psychiatry Association.Diagnostic and statistical manual of mental disorders American Psychiatric Associati[M].5th ed.Arlington:American Psychiatric Publishing,2013:59-65.
[2] Thomas R,Sanders S,Doust J,et al.Prevalence of Attention-Deficit/Hyperactivity disorder:a systematic review and met-analysis [J].Pediatrics,2015,135(4):e994-e1001.
[3] Canadian Attention Deficit Hyperactivity Disorder Resource Alliance ( CADDRA).Canadian ADHD practice guide lines[M].3rd ed.Canada: Toronto CADDRA,2011.
[4] Catala-Lopez F,Hutton B,Nunez-Beltran A,et al.The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: a systematic review with network meta-analysis of randomised trials[J].Systematic Review,2015,4(19):1-10.
[5] 顾静雯,徐通,丁立人,等.哌甲酯控释剂对注意缺陷多动障碍功能的改善[J].中国实用儿科杂志,2013,28(9):698-700.
[6] 韩颖,秦炯,姜玉武,等.哌甲酯治疗不同亚型注意缺陷多动障碍患儿的疗效及影响因素[J].实用儿科临床杂志,2011,26(24):1853-1856.
[7] Kutlu A,Akyol Ardic U,Ercan ES.Effect of methylphenidate on emotional dysregulation in children with attention-deficit/hyperactivity disorder + oppositional defiant disorder/conduct disorder[J].J Clin Psychopharmacol,2017,37(2):220-225.
[8] Golubchik P,Weizman A.The effect of methylphenidate treatment on suspiciousness in children with ADHD alone or comorbid with ODD[J].Int J Psychiatry Clin Pract,2017,29(9):1-6.
[9] Stuckelman ZD,Mulqueen JM,Ferracioli-Oda E,et al.Risk of irritability with psychostimulant treatment in children with adhd: a meta-analysis[J].J Clin Psychiatry,2017,78(6):e648-e655.
[10] 陈敏,华丽,刘琳,等.盐酸哌甲酯控释片治疗儿童注意缺陷多动障碍疗效[J].医药导报,2015,34(10):1318-1321.
[11] 范娟,徐通,赵志民,等.哌甲酯控释剂治疗对注意缺陷多动障碍儿童父母压力的影响[J].中国心理卫生杂志,2011,25(5):339-343.
[12] 李伟,金晶晶,赵钱雷,等.药物治疗可改善注意缺陷多动障碍儿童的核心症状及社会功能[J].中国乡村医药,2016,23(15):19-20.
[13] 俞杰,徐美玉,赵建美,等.学校与家庭行为干预辅佐速释哌甲酯综合治疗儿童注意缺陷多动障碍依从性相关因素分析[J].中国儿童保健杂志,2015,23(3):313-315.
[14] Holmskov M,Ramstad E.Gastrointestinal adverse events during methylphenidate treatment of children and adolescents with attention deficit hyperactivity disorder: a systematic review with meta-analysis and Trial Sequential Analysis of randomised clinical trials[J].PLoS One,2017,12(6):e0178187.
[15] Diez-Suarez A,Vallejo-Valdivielso M.Weight,height,and body mass index in patients with attention-deficit/hyperactivity disorder treated with methylphenidate[J].J Child Adolesc Psychopharmacol,2017,27(8):723-730.
[16] Cooper WO,Habel LA,Sox CM,et al.ADHD drugs and serious cardiovascular events in children and young adults[J].N Engl J Med,2011,365(20):1896-1904.
[17] Quinn PD,Chang Z,Hur K,et al.ADHD medication and substance-related problems[J].Am J Psychiatry,2017,174(9):877-885.
[18] Corp SA,Gitlin MJ,Altshuler LL,et al.A review of the use of stimulants and stimulant alternatives in treating bipolar depression and major depressive disorder[J].J Clin Psychiatry,2014,75(9):1010-1018.
[19] Dalsgaard S,Leckman JF,Mortensen PB,et al.Effect of drugs on the risk of injuries in children with attention deficit hyperactivity disorder: a prospective cohort study[J].Lancet Psychiatry,2015,2(8):702-709.
[20] Van den Ban E,Souverein P,Meijer W,et al.Association between ADHD drug use and injuries among children and adolescents[J].Eur Child Adolesc Psychiatry,2014,23(2):95-102.
[21] Man KKC,Coghill D,Chan Esther W,et al.Association of risk of suicide attempts with methylphenidate treatment[J].JAMA Psychiatry,2017,74(10):1048-1055.
[22] 刘婧,郑毅.《中国注意缺陷多动障碍防治指南》第二版解读[J].中华精神科杂志,2016,49(3):132-135.
[23] 喻东山.托莫西汀与哌甲酯不良反应的比较[J].中国新药与临床杂志,2016,35(5):335-339.
[24] Hanwella R,Senanayake M,de Silva V.Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis[J].BMC Psychiatry,2011,11:176.
[25] 李瑾.盐酸哌甲酯控释片与盐酸托莫西汀治疗儿童注意缺陷多动障碍对比研究[J].中国现代药物应用,2016,24(10):56-57.
[26] Cortese S,Panei P,Arcieri R,et al.Safety of methylphenidate and atomoxetine in children with attention-deficit/hyperactivity disorder (ADHD):Data from the Italian National ADHD Registry L [J].CNS Drugs,2015,9(10):865-877.